ascopost.com
Open in
urlscan Pro
20.40.202.18
Public Scan
Submitted URL: https://www.ascopost.com/
Effective URL: https://ascopost.com/
Submission: On August 25 via automatic, source certstream-suspicious — Scanned from DE
Effective URL: https://ascopost.com/
Submission: On August 25 via automatic, source certstream-suspicious — Scanned from DE
Form analysis 2 forms found in the DOM
GET /search-results/
<form action="/search-results/" method="GET" role="search">
<input class="search" type="text" name="q" placeholder="Search..." required="">
<input class="button-search" type="submit" value=" ">
</form><form class="css-j7vwhm">
<div class="css-vs7qoz">
<h2 id="f502cdbf-a725-4f43-83cc-dface6e55d09" aria-label="Quick question: How can we improve this page? Is anything missing?" class="css-171sweq">Quick question: How can we improve this page? Is anything missing?</h2><textarea type="text"
aria-labelledby="f502cdbf-a725-4f43-83cc-dface6e55d09" required="" placeholder="Please type here..." class="css-skba1g"></textarea>
</div>
<div class="css-16jovna">
<div class="css-v4tztt"><button type="button" kind="primary" disabled="" aria-label="Next question" size="s" class="css-1pymavt">Next</button></div>
<div class="css-12kbg3u">
<a aria-label="Made with Hotjar Surveys" rel="noopener noreferrer" target="_blank" href="https://www.hotjar.com/feedback-surveys?utm_source=client&utm_medium=poll&utm_campaign=insights" class="css-yv6ifa"><img alt="" src="data:image/svg+xml,%0A%3Csvg width='17' height='20' viewBox='0 0 17 20' fill='none' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='M6.68018 8.34533C8.7842 7.17645 11.6658 5.57522 11.6658 0.91507H8.17653C8.17653 3.52244 6.90715 4.22763 4.98564 5.29517C2.88163 6.46448 0 8.065 0 12.7256H3.48929C3.48929 10.1181 4.75867 9.41287 6.68018 8.34533Z' fill='%23FF3200'/%3E%3Cpath d='M12.7195 7.27443C12.7195 9.88194 11.4501 10.5871 9.52861 11.6545C7.42516 12.8234 4.54297 14.4244 4.54297 19.0849H8.03212C8.03212 16.4774 9.3015 15.7722 11.223 14.7047C13.327 13.5358 16.2085 11.935 16.2085 7.27443H12.7195Z' fill='%23FF3200'/%3E%3C/svg%3E%0A" class="css-nql7rx">Made with Hotjar</a>
</div>
</div>
</form>Text Content
Toggle navigation * * About * About The ASCO Post * Editorial Board * Rights and Permissions * Contact * Subscribe * News * FDA Update * Journal Spotlight * Expert's Corner * In the Clinic * * View By Issue * * View All * Meetings * 2024 Debates and Didactics in Hematology and Oncology * European Association for the Study of Diabetes Annual Meeting 2024 * 2024 ASCO Breakthrough * 2024 Pan Pacific Lymphoma Conference * European Hematology Association 2024 Congress * * Calendar * * View All * Topics * Breast Cancer * Lung Cancer * Prostate Cancer * Lymphoma * Cardio-oncology * * View All * Videos * Newsreels * Video Roundtables * Podcasts * Subscribe * Advertisement -------------------------------------------------------------------------------- Advertisement Skin Cancer FIRST-LINE NIVOLUMAB/RELATLIMAB VS NIVOLUMAB/IPILIMUMAB IN ADVANCED MELANOMA In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the two regimens: RELATIVITY-047 and CheckMate 067, respectively. No direct comparisons of the regimens in this setting have been reported previously. Breast Cancer BREAST-CONSERVING SURGERY WITH OR WITHOUT POSTOPERATIVE RADIOTHERAPY IN EARLY-STAGE BREAST CANCER: 30-YEAR UPDATE As reported in The Lancet Oncology by Williams et al, long-term follow-up of the phase III Scottish Breast Conservation Trial indicated that postoperative radiotherapy was associated with a significantly reduced risk of ipsilateral recurrence vs no radiotherapy in patients undergoing breast-conserving surgery for breast cancer, although the difference in risk after 10 years of follow-up was not significant. Pancreatic Cancer METASTATIC PANCREATIC ADENOCARCINOMA: ADDITION OF DEVIMISTAT TO MFFX As reported in the Journal of Clinical Oncology, Philip et al found that the phase III AVENGER 500 study showed no overall survival benefit with devimistat plus modified fluorouracil, oxaliplatin, irinotecan, and leucovorin (mFFX) vs FFX in patients with metastatic pancreatic adenocarcinoma. Advertisement Lung Cancer FDA APPROVES LAZERTINIB WITH AMIVANTAMAB-VMJW FOR EGFR-MUTATED NSCLC The U.S. Food and Drug Administration (FDA) has approved the EGFR inhibitor lazertinib (Lazcluze) in combination with the EGFR/MET-targeting bispecific antibody amivantamab-vmjw (Rybrevant) for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. Multiple Myeloma EXPLORING TARGETED THERAPIES IN MULTIPLE MYELOMA Investigators have explored the multifaceted nature of multiple myeloma and the potential of targeted therapies to treat patients with the disease, as summarized in a review published by Lu et al in Molecular Biomedicine. Lymphoma Leukemia WILLIAM G. WIERDA, MD, PHD, ON CLL/SLL: UPDATED FINDINGS ON IBRUTINIB AND VENETOCLAX Prostate Cancer ALICIA MORGANS, MD, MPH, AND KARIM FIZAZI, MD, PHD, ON PROSTATE CANCER: STUDY FINDINGS ON HEALTH-RELATED QUALITY OF LIFE AND PAIN Bladder Cancer JONATHAN E. ROSENBERG, MD, AND THOMAS POWLES, MD, PHD, ON UROTHELIAL CARCINOMA: EXPERT COMMENTARY ON TWO KEY ABSTRACTS Gynecologic Cancers ALEX ANDREA FRANCOEUR, MD, ON ENDOMETRIAL CANCER AND OBESITY TRENDS Leukemia YUCAI WANG, MD, PHD, ON RICHTER TRANSFORMATION OF CLL: FINDINGS ON COMBINATION THERAPY WITH AN IMMUNE CHECKPOINT INHIBITOR Advertisement Advertisement Aug 25 Today In Oncology FDA APPROVES DARATUMUMAB AND HYALURONIDASE-FIHJ WITH VRD FOR MULTIPLE MYELOMA HYPOFRACTIONATED VS CONVENTIONALLY FRACTIONATED RADIATION AFTER IMPLANT-BASED BREAST RECONSTRUCTION DISPARITIES IN EXPOSURE TO TOBACCO CONTENT ON STREAMING PLATFORMS EARLY INTERVENTIONS MAY IMPROVE LONG-TERM ACADEMIC ACHIEVEMENT IN PEDIATRIC BRAIN TUMOR SURVIVORS THE EVOLVING EPIDEMIOLOGY OF GASTROINTESTINAL STROMAL TUMORS IN MAJOR ORGAN SITES View More Perspectives CONNOR J. KINSLOW AND COLLEAGUES ON BREAST IMPLANT–RELATED CANCERS SIR MURRAY F. BRENNAN ON NAVIGATING THE POST-VACCINE PANDEMIC LORCAN RUANE AND COLLEAGUES ON CARDIOTOXICITY: HOW FAR HAVE WE COME? MARC HURLBERT ON ACCELERATING PROGRESS IN MELANOMA AND CANCER RESEARCH MARY ANN DEAK: A PATIENT PERSPECTIVE View More -------------------------------------------------------------------------------- MORE TOP STORIES Hematologic Malignancies RAMI S. KOMROKJI, MD, ON MYELODYSPLASTIC NEOPLASMS: CLASSIFYING RISKS AMONG SUBSETS OF DISEASE Lymphoma ACALABRUTINIB PLUS CHEMOIMMUNOTHERAPY IMPROVES PROGRESSION-FREE SURVIVAL IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the... Advertisement HYPOFRACTIONATED VS CONVENTIONALLY FRACTIONATED RADIATION AFTER IMPLANT-BASED BREAST RECONSTRUCTION In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated... PAOLO CORRADINI, MD, ON PMBCL AND DLBCL: COMPARING OUTCOMES WITH AXICABTAGENE CILOLEUCEL Cardio-oncology AN INTEGRATED APPROACH TO TREATING CANCER AND CARDIOVASCULAR DISEASE: WHEN ONCOLOGISTS AND CARDIOLOGISTS COLLABORATE At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered... Legislation SCOTUS RULING UPENDS COUNTRY’S REGULATORY FRAMEWORK, THREATENS TO COMPLICATE AND DELAY HEALTH-CARE DELIVERY The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal... DISPARITIES IN EXPOSURE TO TOBACCO CONTENT ON STREAMING PLATFORMS The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization... Hematologic Malignancies Leukemia NIGEL RUSSELL, MD, ON ACUTE MYELOID LEUKEMIA: NEW FINDINGS ON FLAG-IDA AND GEMTUZUMAB OZOGAMICIN Palliative Care ASCO GUIDELINE UPDATE HIGHLIGHTS THE IMPORTANCE OF EARLY INTEGRATION OF PALLIATIVE CARE FOR PATIENTS WITH CANCER Growing awareness of the benefits of palliative care in patients with cancer has prompted ASCO to update its recommendations for clinicians, patients, caregivers, and health-care organizations on integrating palliative care in oncology.1 The updated guideline reinforces prior recommendations in the ... Advertisement EARLY INTERVENTIONS MAY IMPROVE LONG-TERM ACADEMIC ACHIEVEMENT IN PEDIATRIC BRAIN TUMOR SURVIVORS Investigators have found that providing early developmental resources may help reduce the adverse effects of brain tumors and cancer therapy on the academic achievement of young pediatric cancer survivors, according to a recent study published by Somekh et al in the Journal of the National Cancer... ASCO Post X Feed Social Media Hub by Load More Bots not welcome here -------------------------------------------------------------------------------- © 2024 HSP News Service, L.L.C. * Editorial Board * Advertising * Disclosures * Contact * Privacy Policy * Disclaimer * ASCO.org QUICK QUESTION: HOW CAN WE IMPROVE THIS PAGE? IS ANYTHING MISSING? Next Made with Hotjar